|
| 36780934 | Correlation between chylomicronemia diagnosis scores and post-heparin lipoprotein lipase activity. | | 2023 |
| 38030518 | Comparison of the burden of familial hypercholesterolemia between two cohorts of French Canadians hospitalized 25 years apart for coronary heart disease. | | 2023 |
| 38095804 | Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia. | | 2023 |
| 37626170 | RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. | Nat Med | 2023 |
| 36586484 | Comparison of Three Methods for LDLC Calculation for Cardiovascular Disease Risk Categorisation in Three Distinct Patient Populations. | | 2023 |
| 36879129 | Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. | Nat Med | 2023 |
| 37130090 | 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. | | 2023 |
| 37370069 | Post-prandial analysis of fluctuations in the platelet count and platelet function in patients with the familial chylomicronemia syndrome. | | 2023 |
| 37100699 | Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial. | | 2023 |
| 36727130 | Atherosclerotic plaque regression in homozygous familial hypercholesterolaemia: a case report of a long-term lipid-lowering therapy involving LDL-receptor-independent mechanisms. | | 2023 |
| 34774719 | Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry. | Canadian Journal of Cardiology | 2022 |
| 35902351 | Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. | J Clin Lipidol | 2022 |
| 36342163 | Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. | N Engl J Med | 2022 |
| 36210291 | Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia. | Journal of Clinical Lipidology | 2022 |
| 36075246 | Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. | Lancet Diabetes and Endocrinology,The | 2022 |
| 35860753 | Palmar Striated Xanthomas in Clinical Practice. | Journal of the Endocrine Society | 2022 |
| 35789567 | Visceral adiposity is associated with metabolic profiles predictive of type 2 diabetes and myocardial infarction. | | 2022 |
| 35718690 | A More Atherogenic Lipoprotein Status Is Present in Adults With Type 2 Diabetes Mellitus Than in Those Without With Equivalent Degrees of Hypertriglyceridemia. | | 2022 |
| 35469449 | Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia. | | 2022 |
| 33624041 | Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. | Eur J Prev Cardiol | 2022 |
| 35194765 | A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. | Advances in Therapy | 2022 |
| 35025993 | Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. | Eur Heart J | 2022 |
| 34472586 | Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. | European Heart Journal | 2021 |
| 31900429 | A variant near DHCR24 associates with microstructural properties of white matter and peripheral lipid metabolism in adolescents. | Molecular Psychiatry | 2021 |
| 34238441 | Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia. | Journal of the American College of Cardiology | 2021 |
| 33910931 | Genetic burden linked to founder effects in Saguenay-Lac-Saint-Jean illustrates the importance of genetic screening test availability. | J Med Genet | 2021 |
| 33798466 | Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. | Lancet Diabetes and Endocrinology,The | 2021 |
| 34051877 | Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. | Lancet Respir Med | 2021 |
| 33572376 | Non-Alcoholic Fatty Liver in Patients with Chylomicronemia. | Journal of Clinical Medicine | 2021 |
| 33567208 | Evinacumab for Homozygous Familial Hypercholesterolemia. Reply. | New England Journal of Medicine | 2021 |
| 33662430 | Sex differences in markers of metabolic syndrome and adipose tissue inflammation in obesity-prone, Osborne-Mendel and obesity-resistant, S5B/Pl rats. | Life Sciences | 2021 |
| 34035401 | Genetics of symptom remission in outpatients with COVID-19. | Sci Rep | 2021 |
| 33386398 | SARS-CoV-2 Receptor ACE2 Gene Is Associated with Hypertension and Severity of COVID 19: Interaction with Sex, Obesity, and Smoking. | Am J Hypertens | 2021 |
| 35316922 | Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE. | Arch Med Sci | 2021 |
| 32727960 | Gene expression profiles of recurrent acute pancreatitis risk in patients with sustained chylomicronemia. | Endocrine Journal | 2020 |
| 32430061 | Association of common gene-smoking interactions with elevated plasma apolipoprotein B concentration. | Lipids in Health and Disease | 2020 |
| 32010872 | Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in Hypertriglyceridemia. | Journal of the Endocrine Society | 2020 |
| 32487261 | The burden of familial chylomicronemia syndrome in Canadian patients. | Lipids Health Dis | 2020 |
| 32473640 | Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study. | Lipids in Health and Disease | 2020 |
| 31973581 | Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. | Expert Opinion on Drug Discovery | 2020 |
| 31753053 | DNA methylation at gene locus mediates the association between maternal total cholesterol changes in pregnancy and cord blood leptin levels. | Journal of Developmental Origins of Health and Disease | 2020 |
| 33375401 | Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia. | Journal of Clinical Medicine | 2020 |
| 32537545 | Dissection of Clinical and Gene Expression Signatures of Familial versus Multifactorial Chylomicronemia. | Journal of the Endocrine Society | 2020 |
| 32646561 | Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial. | Journal of the American College of Cardiology | 2020 |
| 33196153 | Evinacumab in Patients with Refractory Hypercholesterolemia. | New England Journal of Medicine | 2020 |
| 33032940 | Relative effect of hypertriglyceridemia on non-HDLC and apolipoprotein B as cardiovascular disease risk markers. | Journal of Clinical Lipidology | 2020 |
| 32919280 | No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. | Atherosclerosis | 2020 |
| 32860031 | Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. | European Heart Journal | 2020 |
| 33340164 | Adiposity-related insulin resistance and thickness of the cerebral cortex in middle-aged adults. | Journal of Neuroendocrinology | 2020 |
| 32906018 | Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience. | Atherosclerosis | 2020 |